The natural peptide somatostatin is a hormone distributed in the Central nervous system and peripheral tissues. Natural somatostatin has a variety of physiol. effects, including its role as a neurotransmitter and neuromodulator of the Central nervous system, a regulatory hormone in the gastrointestinal tract and pancreas and an inhibitor of growth hormone release and TSH in the pituitary gland. Due to a number of physiol. effects, natural somatostatin has been studied for the treatment of acromegaly and endocrine bowel tumors. Despite many potential uses, clin. administration of somatostatin is limited by a very short half life (2-3 min), requiring continuous i.v. infusion and resulting in reversible hypersecretion of the hormone after infusion. To overcome these limitations, peptide amino acid analogs of natural somatostatin were developed. Compared to natural hormone, analogs have a higher selectivity for certain receptor subtypes that allows for greater specificity of growth hormone suppression, longer therapeutic action and the possibility of alternative modes of administration other than the i.v. infusion. First-generation somatostatin analogs, octreotide and lanreotide, are the first medical option for most patients due to their longer market presence and Consequently extensive experience with these drugs and their favorable efficacy and safety profile. However, a significant proportion of patients with acromegaly do not achieve biochem. control after surgery, radiotherapy and / or treatment with first-generation somatostatin analogs. In this case, treatment with pasireotide is indicated. All therapeutic systems for the delivery of somatostatin analogs on the market are administered parenterally. In addition to fast-acting forms (Solutions), which are dosed several times a day, long-acting therapeutic systems for one-month application have been developed and prolonged action is achieved by incorporation into biodegradable PLGA microparticles. In addition, the self-aggregation ability of lanreotide into hollow nanotubes allows its prolonged release from the supersaturated aqueous solution Due to the large financial incentive for pharmaceutical companies, new, potentially more effective and better tolerated therapeutic systems are being developed for the delivery of somatostatin analogs and the treatment of acromegaly.